Q-Line Biotech Ltd IPO

Established manufacturing capabilities with focus on R&D, Reverse Engineering and quality control.

Diversified product portfolio with focus on IVD industry.

Widespread distribution network with a presence across all four regions.

Long standing relationships with customers.

Any disruption, stoppage, slowdown or shutdown in the company manufacturing facilities or process or research and development activities could adversely affect its business, financial condition, cash flows and results of operations.

Any delay, interruption or reduction in the supply of the company raw materials, trade goods from its suppliers and manufacturers both domestic and imported, or an increase in the costs of such raw materials, trade goods may adversely impact the pricing and supply of the company products and has an adverse effect on the company business, financial condition, cash flows and results of operations.

The company business is dependent on the sale of its products through distributors which also include the company group entity POCT services. The loss of any of these distributors or third parties for any reason may adversely affect the marketing and distribution of its products and could negatively impact the company business, results of operations, financial conditions and cash flows.

The company is dependent on certain key suppliers to procure a significant portion of the company Raw material for production of reagents and for traded machines. Any denial of supplies or loss of the relationship with them could result in disruption in its operations, which could has an adverse effect on the company business, financial condition, results of operations and cash flows.